Bristol-Myers Squibb Company (BMY)

53.48
NYSE : Health Care
Prev Close 53.44
Day Low/High 53.15 / 53.71
52 Wk Low/High 46.01 / 77.12
Avg Volume 12.04M
Exchange NYSE
Shares Outstanding 1.65B
Market Cap 88.04B
EPS 2.70
P/E Ratio 20.17
Div & Yield 1.56 (2.90%)

Latest News

Here's Why You Should Hope For Panic: Cramer's 'Mad Money' Recap (Friday 4/21/17)

Here's Why You Should Hope For Panic: Cramer's 'Mad Money' Recap (Friday 4/21/17)

Jim Cramer looks at how the French elections are smacking the U.S stock markets. Plus, he has the week-ahead game plan for oil and stocks.

Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval Of Opdivo (nivolumab) For The Treatment Of Patients With Previously Treated Locally Advanced Or Metastatic Urothelial Carcinoma, A Type Of Bladder Cancer

Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval Of Opdivo (nivolumab) For The Treatment Of Patients With Previously Treated Locally Advanced Or Metastatic Urothelial Carcinoma, A Type Of Bladder Cancer

Bristol-Myers Squibb Company (NYSE:BMY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the approval of Opdivo (nivolumab) for the...

Intermediate Trade: Bristol-Myers Squibb

Intermediate Trade: Bristol-Myers Squibb

Consider this BMY bullishly biased, near-the-money vertical call spread.

Bristol-Myers Squibb And Nordic Bioscience Announce Collaboration For Fibrosis Biomarker Technology

Bristol-Myers Squibb And Nordic Bioscience Announce Collaboration For Fibrosis Biomarker Technology

Bristol-Myers Squibb Company (NYSE:BMY) and Nordic Bioscience, a Danish company specializing in biomarker technologies, today announced a collaboration agreement to develop biomarker technology to potentially aid in...

Takeaways and Observations; The Good, the Bad and the Ugly: Doug Kass' Views

Takeaways and Observations; The Good, the Bad and the Ugly: Doug Kass' Views

Doug Kass shares his thoughts on Apple, Allergan and Western Digital.

Biotech Movers: Synergy, Biogen, Insys

Biotech Movers: Synergy, Biogen, Insys

Synergy Pharmaceuticals, Biogen and Insys Therapeutics were among the biotech stock movers in premarket trading on Thursday.

Biogen Licenses Phase 2 Anti-Tau Antibody From Bristol-Myers Squibb

Biogen Licenses Phase 2 Anti-Tau Antibody From Bristol-Myers Squibb

Biogen (NASDAQ:BIIB) today announced an agreement to exclusively license BMS-986168, a Phase 2-ready experimental medicine with potential in Alzheimer's disease (AD) and progressive supranuclear palsy (PSP), from...

Bristol-Myers Squibb Enters Into Separate Agreements With Biogen And Roche To License Anti-eTau And Anti-Myostatin Compounds, Respectively

Bristol-Myers Squibb Enters Into Separate Agreements With Biogen And Roche To License Anti-eTau And Anti-Myostatin Compounds, Respectively

Bristol-Myers Squibb Company  (NYSE:BMY) today announced that it has entered into two separate agreements to license BMS-986168, an anti-eTau compound in development for Progressive Supranuclear Palsy (PSP), to...

Jim Cramer -- Eli Lilly Is the New 'Darling' of Big Pharma

Jim Cramer -- Eli Lilly Is the New 'Darling' of Big Pharma

Eli Lilly has become the new go-to name in the pharmaceutical space, even over Johnson & Johnson, Cramer said.

Whole Foods Shares Spike Under Pressure from Jana

Whole Foods Shares Spike Under Pressure from Jana

The activist investor launched an insurgency campaign at the organic grocer, seeking to press the company to consider strategic options and make other share-price improving changes.

Jim Cramer Says Incyte Has an Amazing Pipeline of Treatments

Jim Cramer Says Incyte Has an Amazing Pipeline of Treatments

'These companies are all assessing the Trump effect,' Cramer said.

Jim Cramer -- Incyte Stock Is Red-Hot, Worth More Than $200 in a Takeout

Jim Cramer -- Incyte Stock Is Red-Hot, Worth More Than $200 in a Takeout

Incyte has been doing great, locking in deals with Bristol-Myers and Merck. It's worth a lot more in a takeover situation, Cramer said.

Why AbbVie Will be an Incredible Money-Making Machine in an Overvalued Stock Market

Why AbbVie Will be an Incredible Money-Making Machine in an Overvalued Stock Market

The pharmaceutical giant has an attractive yield supported by double-digit earnings growth.

As Biotech Roars Back, Amgen Remains Dirt Cheap

As Biotech Roars Back, Amgen Remains Dirt Cheap

The biotechnology sector is enjoying robust recovery, driving Big Pharma shares to lofty levels. But this biotech stalwart is a great value play now.

Profit-Taking Is Only Natural: Cramer's 'Mad Money' Recap (Monday 4/3/17)

Profit-Taking Is Only Natural: Cramer's 'Mad Money' Recap (Monday 4/3/17)

Jim Cramer says what's more noteworthy than the pullback is the day's strong rebound.

Cramer: Stay the Course, but Keep Cash Handy

Cramer: Stay the Course, but Keep Cash Handy

It's pretty normal to have profit-taking after such a strong first quarter.

Bristol-Myers Squibb Announces Results From CheckMate -143, A Phase 3 Study Of Opdivo (nivolumab) In Patients With Glioblastoma Multiforme

Bristol-Myers Squibb Announces Results From CheckMate -143, A Phase 3 Study Of Opdivo (nivolumab) In Patients With Glioblastoma Multiforme

Bristol-Myers Squibb Company (NYSE:BMY) today announced that CheckMate -143, a randomized Phase 3 clinical trial evaluating the efficacy and safety of Opdivo in patients with first recurrence of glioblastoma multiforme...

Opdivo (nivolumab) In Combination With Yervoy (ipilimumab) And Opdivo Monotherapy Significantly Improved Overall Survival Versus Yervoy Alone In Patients With Previously Untreated Advanced Melanoma

Opdivo (nivolumab) In Combination With Yervoy (ipilimumab) And Opdivo Monotherapy Significantly Improved Overall Survival Versus Yervoy Alone In Patients With Previously Untreated Advanced Melanoma

Bristol-Myers Squibb Company (NYSE:BMY) today announced the first overall survival (OS) data from the Phase 3 CheckMate -067 clinical trial.

Five-Year Survival Observed With Opdivo (nivolumab) In Patients With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC), In Phase 1 Study CA209-003

Five-Year Survival Observed With Opdivo (nivolumab) In Patients With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC), In Phase 1 Study CA209-003

Bristol-Myers Squibb Company (NYSE:BMY) today announced the first report of five-year overall survival (OS) data from the Phase 1 dose-ranging study CA209-003 evaluating Opdivo in patients with previously treated...

Incyte Cancer Immunotherapy Drug Is Object of Desire for Two Big Pharma Rivals

Incyte Cancer Immunotherapy Drug Is Object of Desire for Two Big Pharma Rivals

The broad development plan across five different types of cancer widens Incyte's lead over other IDO inhibitors in clinical development.

Cramer: We Have Nothing to Distinguish the Stocks Right Now

Cramer: We Have Nothing to Distinguish the Stocks Right Now

We know that we are in the era when index managers are ascendant.

Bristol-Myers Squibb And Incyte To Advance The Combination Of Opdivo (nivolumab) And Epacadostat Into First-line Registrational Trials

Bristol-Myers Squibb And Incyte To Advance The Combination Of Opdivo (nivolumab) And Epacadostat Into First-line Registrational Trials

Bristol-Myers Squibb Company (NYSE:BMY) and Incyte Corporation (Nasdaq:INCY) today announced the companies have agreed to advance their clinical development program evaluating the combination of epacadostat,...

Market Turns Down the Volume

Is it just moving up on air?

Must-Own Dividend Dates for April

Mark your calendars!

Bristol-Myers Squibb Enters Collaboration To Leverage Foundation Medicine's Molecular Information Platform To Identify Predictive Biomarkers Across Multiple Tumor Types And Immunotherapy Agents

Bristol-Myers Squibb Enters Collaboration To Leverage Foundation Medicine's Molecular Information Platform To Identify Predictive Biomarkers Across Multiple Tumor Types And Immunotherapy Agents

Bristol-Myers Squibb Company (NYSE:BMY) and Foundation Medicine (NASDAQ:FMI) today announced a collaboration that leverages Foundation Medicine's comprehensive genomic profiling and molecular information solutions...

Parker Institute For Cancer Immunotherapy, Bristol-Myers Squibb And The Cancer Research Institute Announce Collaboration To Accelerate Immuno-Oncology Research

Parker Institute For Cancer Immunotherapy, Bristol-Myers Squibb And The Cancer Research Institute Announce Collaboration To Accelerate Immuno-Oncology Research

The Parker Institute for Cancer Immunotherapy, Bristol-Myers Squibb Company (NYSE: BMY) and the Cancer Research Institute (CRI) today announced a multi-year clinical research collaboration to coordinate and rapidly...